๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nasopharyngeal Carcinoma
Clinical trial register · China

Nasopharyngeal Carcinoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 66 Nanning 13 Zhongshan 12 Fuzhou 9 Wuzhou 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University56 Fudan University5 Zhejiang Cancer Hospital4 XIANG YANQUN3 Zhongshan People's Hospital, Guangdong, China3
Site location
Guangzhou66 Nanning13 Zhongshan12 Fuzhou9 Wuzhou7
All 45 locations
Target enrolment
to

Nasopharyngeal Carcinoma trials in China

102 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
NCT07824856Nasopharyngeal Carcinoma, Neoplasm Metastasis, Lung Metastases, Liver Metastases
Sun Yat-sen University
Phase 2
138
Guangzhou
2026-10
Recruiting
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NCT07584499Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
Sun Yat-sen University
Phase 1
51
Guangzhou
2026-05-30
Not yet open
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
NCT07540390Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
442
Guangzhou
2026-05-08
Recruiting
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.
NCT06059261Nasopharyngeal Carcinoma
Chongqing University Cancer Hospital
Phase 2
30
Chongqing
2026-02-09
Not yet open
Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma
NCT05912582Nasopharyngeal Carcinoma
Jiangsu Cancer Institute & Hospital
Observational
60
Nanjing
2025-12-25
Recruiting
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
NCT07328854Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
NCT06912711Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
70
Guangzhou
2025-05-16
Recruiting
Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma
NCT07000643Nasopharyngeal Carcinoma
Man Hu
Phase 3
386
Jinan
2025-05-07
Not yet open
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112TPF, Immunotherapy, Nasopharyngeal Carcinoma, Phase II Clinical Study
Weiwei Zhang
Phase 2
35
Chengdu
2025-01-20
Recruiting
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
NCT06851247Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
47
Guangzhou
2025-01-03
Recruiting
Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC
NCT06752239Nasopharyngeal Carcinoma, Quality of Life, Thyroid Diseases, Radiotherapy Side Effect
Jiangxi Provincial Cancer Hospital
Phase 3
474
Nanchang
2025-01-01
Active, closed
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)
NCT06629597Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
400
Guangzhou
2024-12-31
Recruiting
Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients
NCT06389201Nasopharyngeal Carcinoma
Affiliated Hospital of Nantong University
Not applicable
30
Nantong
2024-08-01
Recruiting
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
NCT06675214Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
586
Zhuhai
2024-07-30
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
NCT06323239Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
Deep Learning-based sbORN Diagnostic Model
NCT06463392Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
312
Guangzhou
2024-07-01
Recruiting
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT06475300Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
570
Guangzhou
2024-06-25
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
NCT06438627Nasopharyngeal Carcinoma
XIANG YANQUN
Phase 3
164
Guangzhou
2024-05-30
Recruiting
Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
NCT06445088Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Recruiting
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
NCT06383780Nasopharyngeal Carcinoma
XIANG YANQUN
Phase 3
90
Guangzhou
2024-05-15
Not yet open
KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial
NCT06370026Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase EARLY_PHASE1
12
Guangzhou
2024-05-01
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
NCT06533267Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery
Sun Yat-sen University
Not applicable
442
Zhuhai
2024-03-25
Recruiting
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma
NCT06277050Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy
Jiangxi Provincial Cancer Hospital
Phase 3
264
Ganzhou, Guangzhou, Nanchang
2024-03-07
Recruiting
De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for Nasopharyngeal Carcinoma
NCT06313450Nasopharyngeal Carcinoma, Radiotherapy; Complications, IMMUNOTHERAPY
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Recruiting
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
NCT06307314Nasopharyngeal Carcinoma, Head and Neck Cancer, Radiotherapy-induced Oral Mucositis, Biomarker
Nanfang Hospital, Southern Medical University
Observational
300
Guangzhou, Fuzhou, Huizhou, Jieyang, Meizhou
2024-02-01
Recruiting
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT05956587Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
NCT06321939Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Hunan Cancer Hospital
Observational
50
Changsha
2024-01-11
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Not yet open
Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
NCT06095167Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Phase 3
476
Fuzhou
2024-01-01
Active, closed
Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study
NCT06881225Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Recruiting
The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC
NCT06182657Nasopharyngeal Carcinoma, Pathologic Complete Response, Tumor Microenvironment
Jiangxi Provincial Cancer Hospital
Observational
300
Nanchang
2024-01-01
Active, closed
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
NCT06118333Nasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
386
Guangzhou
2023-12-04
Recruiting
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
NCT06177301Nasopharyngeal Carcinoma
Fudan University
Phase 3
266
Shanghai
2023-12-01
Recruiting
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
NCT06688760Nasopharyngeal Carcinoma, Surgery, Radiotherapy
Ming-Yuan Chen
Not applicable
86
Guangzhou, Zhuhai
2023-11-01
Recruiting
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
NCT06092957Nasopharyngeal Carcinoma, De-escalation Therapy
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Recruiting
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
NCT06055816Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
40
Hangzhou
2023-09-28
Active, closed
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
NCT05979961Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Recruiting
GNT Induction Treatment in Locally Advanced NPC
NCT06026878Nasopharyngeal Carcinoma
Air Force Military Medical University, China
Phase 3
228
Xi'an
2023-09-01
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Recruiting
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
NCT05994170Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy
Zhongshan People's Hospital, Guangdong, China
Not applicable
454
Zhongshan
2023-08-04
Active, closed
Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
NCT05587374Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma
NCT05877872Nasopharyngeal Carcinoma, De-escaltion Therapy
Sun Yat-sen University
Phase 3
424
Guangzhou
2023-05-20
Recruiting
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
NCT05854849Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
244
Guangzhou
2023-05-01
Active, closed
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
NCT05869227Nasopharyngeal Carcinoma, Maintenance Therapy
XIANG YANQUN
Phase 3
166
Guangzhou
2023-04-28
Active, closed
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05813626Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
89
Hangzhou
2023-04-21
Not yet open
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT05780294Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Recruiting
Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
NCT05884983Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China
Observational
12,000
Zhongshan
2023-02-01
Recruiting
Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma
NCT05587543Nasopharyngeal Carcinoma
Fudan University
Phase EARLY_PHASE1
24
Shanghai
2022-12-28
Not yet open
A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy
NCT05622474Nasopharyngeal Carcinoma
Sun Yat-sen University
Not applicable
236
Guangzhou
2022-11-30
Active, closed
SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
NCT05524168Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
41
Guangzhou
2022-11-25
Active, closed
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
NCT05531916Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sun Yat-sen University
Not applicable
182
Guangzhou
2022-11-21
Recruiting
Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05527470Nasopharyngeal Carcinoma
Wei Jiang
Phase 3
440
Guilin, Wuzhou
2022-11-11
Recruiting
Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
NCT06529562Nasopharyngeal Carcinoma
Ming-Yuan Chen
Not applicable
384
Zhuhai
2022-11-01
Active, closed
Optimization of Cervical Nodal CTV for Early and Medium Stage NPC
NCT05145660Nasopharyngeal Carcinoma
Yi Junlin
Phase 3
414
Beijing
2022-09-01
Recruiting
Radiotherapy Combined With Endostatin and Capecitabine for NPC
NCT05514275Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
41
Hangzhou, Jiaxing, Jinhua, Lishui, Ningbo, Quzhou
2022-08-01
Recruiting
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
NCT05707819Nasopharyngeal Carcinoma, Sintilimab
Cancer Hospital of Guangxi Medical University
Observational
43
Nanning
2022-07-30
Active, closed
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05340270Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
Guangxi Medical University
Phase 2
150
Nanning
2022-07-15
Recruiting
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
NCT05447169Nasopharyngeal Carcinoma
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Active, closed
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05211232Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
450
Zhanjiang, Wuzhou, Guiyang, Changsha
2022-06-10
Active, closed
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT05294172Nasopharyngeal Carcinoma, Recurrent or Metastatic
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
295
Beijing
2022-06-07
Recruiting
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
NCT05352321Nasopharyngeal Carcinoma
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Active, closed
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
NCT05201859Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
NCT05304468Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Recruiting
Nituzumab (Taixinsheng ยฎ๏ผ‰ A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma
NCT05508347Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2
170
Chengdu
2022-04-20
Recruiting
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
NCT05342792Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
NCT05340491Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Recruiting
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
NCT05290194Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 2
28
Zhuhai
2022-03-28
Recruiting
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
NCT05147844Nasopharyngeal Carcinoma
Xinqiao Hospital of Chongqing
Phase 2
40
Chongqing
2022-03-01
Active, closed
Penpulimab Combined With GP ยฑ Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05193617Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
104
Guangzhou
2022-01-20
Recruiting
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
NCT05772208Nasopharyngeal Carcinoma
Fudan University
Phase 3
459
Shanghai
2022-01-01
Recruiting
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
NCT04813705Nasopharyngeal Carcinoma
Taizhou Hospital
Phase 2
93
Taizhou
2022-01-01
Recruiting
Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy
NCT05674305Nasopharyngeal Carcinoma
Fudan University
Phase 3
366
Shanghai
2022-01-01
Recruiting
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
NCT05126160Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Observational
494
Wuhan, Ningbo, Wenzhou, Hangzhou
2021-11-05
Active, closed
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04974398Nasopharyngeal Carcinoma
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Recruiting
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
NCT04436965Nasopharyngeal Carcinoma, Nutrition Therapy
Sun Yat-sen University
Phase 3
266
Guangzhou
2021-08-16
Active, closed
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
NCT04907370Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
Not yet open
An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC
NCT04890522Nasopharyngeal Carcinoma, Metastasis, Chemotherapy, Immunotherapy
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma
NCT04944914Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
188
Guangzhou
2021-06-01
Recruiting
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
NCT04778956Nasopharyngeal Carcinoma, PD-1, Surgery
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Active, closed
Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma
NCT04517214Nasopharyngeal Carcinoma
Fudan University
Phase 2
100
Shanghai
2020-11-01
Recruiting
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
NCT04448522Nasopharyngeal Carcinoma, Radiotherapy, Chemotherapy
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Active, closed
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
NCT04456322Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
381
Guangzhou
2020-08-17
Recruiting
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
NCT04437329Nasopharyngeal Carcinoma
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 3
352
Guangzhou
2020-08-01
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
NCT04544969Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2020-04-01
Recruiting
Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
NCT04085900Nasopharyngeal Carcinoma
Zhongshan People's Hospital, Guangdong, China
Observational
40,000
Zhongshan, Wuzhou
2020-04-01
Active, closed
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
NCT04223024Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2
246
Guangzhou
2020-01-31
Recruiting
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
NCT04136886Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
346
Guangzhou
2020-01-01
Active, closed
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
NCT04384627Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy
Sun Yat-sen University
Phase 3
445
Foshan, Zhongshan
2019-12-01
Active, closed
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
Sun Yat-sen University
Phase 3
468
Guangzhou
2019-04-03
Active, closed
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
NCT03306121Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
322
Guangzhou
2017-11-13
Recruiting
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
NCT03353467Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
Sun Yat-sen University
Not applicable
228
Guangzhou, Zhongshan, Nanning
2017-10-01
Rows per page Showing 1–100 of 102
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/condition/nasopharyngeal-carcinoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 102 of those studies listing the condition Nasopharyngeal Carcinoma.

How many Nasopharyngeal Carcinoma trials are recruiting in China?

65 of the 102 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 10 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nasopharyngeal Carcinoma), 102 studies
PhaseStudiesRecruitingShare
Phase 3482847.1%
Phase 2261525.5%
Observational141213.7%
Not applicable1089.8%
Phase EARLY_PHASE1212%
Phase 1111%
Phase 2/3101%

Most active sponsors

Lead sponsors with the most studies (Nasopharyngeal Carcinoma)
Lead sponsorStudiesRecruiting
Sun Yat-sen University5631
Fudan University54
Zhejiang Cancer Hospital43
Jiangxi Provincial Cancer Hospital33
Ming-Yuan Chen33
Sichuan Baili Pharmaceutical Co., Ltd.32
XIANG YANQUN32
Zhongshan People's Hospital, Guangdong, China33
Affiliated Cancer Hospital & Institute of Guangzhou Medical University11
Affiliated Hospital of Nantong University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.